title: Cardioprotective medication use after renal transplantation.
abstract: Cardiovascular disease is the leading cause of death in renal transplant patients. This study compares the use of cardioprotective medications in adult kidney transplant recipients at a single center with recommendations, which have been validated in the general population. Cardioprotective medication use was retrospectively collected post-renal transplant. Patients were defined as high risk if they had pre-transplant coronary heart disease or equivalent risk. "Optimal" treatment was defined as a patient receiving aspirin, statin, angiotensin-converting enzyme inhibitors/angiotensin receptor blocker, and a beta-blocker according to cardiovascular risk. The percentage of high-risk patients optimally treated at one, three, six, and 12 months was 7.7%, 11.5%, 17.6%, and 18.8%, respectively. Although the use of cardioprotective medications was evident in transplant recipients, opportunities exist to increase the use of optimal cardioprotective regimens after renal transplantation.
authors.affiliation: Department of Pharmacy, The Methodist Hospital The Kidney Institute, Houston, TX, USA. KLDawson@tmhs.org
authors.forename: Kyle L
authors.initials: KL
authors.lastname: Dawson
authors.forename: Samir J
authors.initials: SJ
authors.lastname: Patel
authors.forename: David
authors.initials: D
authors.lastname: Putney
authors.forename: Wadi N
authors.initials: WN
authors.lastname: Suki
authors.forename: A
authors.initials: A
authors.lastname: Osama Gaber
mesh_terms: D000328:Adult; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate
chemical_list: D002316:Cardiotonic Agents